Trial Profile

A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
Indications Adenocarcinoma; Carcinoma; Endocrine gland neoplasms; Paraganglioma; Parathyroid cancer; Phaeochromocytoma; Pituitary cancer; Solid tumours; Thyroid cancer
Focus Therapeutic Use

03 Sep 2020 Status changed from not yet recruiting to withdrawn prior to enrolment as no participant registered.
19 Mar 2020 Planned initiation date changed from 15 Feb 2020 to 30 Apr 2020.
23 Jan 2020 Planned initiation date changed from 13 Dec 2019 to 15 Feb 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com